Baheal Pharmaceutical Partners with Takeda to Boost Drug Commercialization in China
China-based health services and distribution giant Baheal Pharmaceutical Group has entered into a partnership with...
Belief-Delivery BioMed’s BBM-H901 Granted BTD for Hemophilia B Prevention
The Center for Drug Evaluation (CDE) website indicates that Shanghai Belief-Delivery BioMed Co., Ltd’s injectable...
Wyze Biotech Raises RMB59m to Advance DNT Cell Therapies
Wyze Biotech Co., Ltd, a Guangdong-based developer of off-the-shelf universal DNT cell therapies, has reportedly...
Sanjin Pharma’s Subsidiary Gets NMPA Nod for BC007 Cancer Study
China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Biopharmaceutical...
I-Mab and AbbVie End CD47 Antibody Trial but Continue Collaboration
China-based biotech I-Mab (NASDAQ: IMAB) filed with the US Securities and Exchange Commission (SEC) that...
Menovo Pharmaceutical Plans RMB892m Private Placement to Boost API Production
China-based Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has announced plans to raise up to...
BeiGene Partners with Ontada to Accelerate RWE Development in US Oncology Market
China-based biotech company BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced that it has signed...
Grand Pharmaceutical’s Carglumic Acid Set for Priority Review by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Grand Pharmaceutical Group Limited’s (HKG:...
Ascletis Pharma’s Gannex Initiates DDI Study for ASC42 in PBC
Ascletis Pharma Inc. (HKG: 1672) announced that its wholly – owned US unit, Gannex, has...
Venus Medtech’s VenusP-Valve Used Again in US Compassionate Case
Venus Medtech (Hangzhou) Inc. (HKG: 2500) announced the second US market compassionate use of its...
Luye Pharma’s Goserelin Acetate Injectable Accepted for Breast Cancer Review
China-based Luye Pharma Group (HKG: 2186) announced that another market filing for its goserelin acetate...
Healthnice Pharma Raises RMB100m to Expand Product Pipeline and R&D Team
China-based Nanjing Healthnice Pharmaceutical Technology Co., Ltd has reportedly raised RMB100 million (USD14.8 million) in...
Healthnice Pharma Raises RMB100m to Expand Product Pipeline and R&D Team
China-based Nanjing Healthnice Pharmaceutical Technology Co., Ltd has reportedly raised RMB100 million (USD14.8 million) in...
Gilead Transfers Trodelvy Asian Rights to Everest Medicines for USD280m
US pharmaceutical major Gilead Sciences Inc. (NASDAQ: GILD) today announced an agreement with Everest Medicines...
CDE Prioritizes Review for Sanofi’s Nexviazyme and WinHealth’s Ravicti
The Center for Drug Evaluation (CDE) website indicates that two drugs have been selected for...
Henlius Biotech’s HanBeiTai sBLA Accepted for HCC Treatment Review
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that a supplementary Biologic License Application (sBLA) for...
Alphamab Oncology Doses First Patient in KN046-209 Study for NSCLC
China-based Alphamab Oncology (HKG: 9966) announced the first patient dosing in the multi-center, open-label Phase...
Roche’s Rozlytrek Wins NMPA Approval for ROS1+ NSCLC Treatment
Swiss pharmaceutical giant Roche’s China unit announced that it has received market approval from the...
EQRx Accelerates US Development of Two Chinese-Licensed Cancer Drugs
US-based pharma EQRx Inc. (Nasdaq: EQRX) has revealed its latest plans to accelerate the US...
Novartis Aims for China to Be Second – Largest Market by 2024
Dan Brindle, head of Novartis AG’s (NYSE: NVS) China operations, recently spoke with Xinhua news...